JP2021501199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501199A5 JP2021501199A5 JP2020543248A JP2020543248A JP2021501199A5 JP 2021501199 A5 JP2021501199 A5 JP 2021501199A5 JP 2020543248 A JP2020543248 A JP 2020543248A JP 2020543248 A JP2020543248 A JP 2020543248A JP 2021501199 A5 JP2021501199 A5 JP 2021501199A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- crystalline salt
- peak
- diffraction pattern
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 23
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 201000011510 cancer Diseases 0.000 claims 13
- 238000000634 powder X-ray diffraction Methods 0.000 claims 12
- 102000018471 Proto-Oncogene Proteins B-raf Human genes 0.000 claims 8
- 108010091528 Proto-Oncogene Proteins B-raf Proteins 0.000 claims 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- 206010009944 Colon cancer Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 230000001594 aberrant effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 2
- 238000002411 thermogravimetry Methods 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 claims 1
- 102000009929 raf Kinases Human genes 0.000 claims 1
- 108010077182 raf Kinases Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000001384 succinic acid Substances 0.000 claims 1
- 238000001757 thermogravimetry curve Methods 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023021816A JP2023062074A (ja) | 2017-10-26 | 2023-02-15 | Ｂ－ｒａｆキナーゼ阻害物質の結晶塩 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762577313P | 2017-10-26 | 2017-10-26 | |
| US62/577,313 | 2017-10-26 | ||
| PCT/US2018/057792 WO2019084459A1 (en) | 2017-10-26 | 2018-10-26 | CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023021816A Division JP2023062074A (ja) | 2017-10-26 | 2023-02-15 | Ｂ－ｒａｆキナーゼ阻害物質の結晶塩 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501199A JP2021501199A (ja) | 2021-01-14 |
| JP2021501199A5 true JP2021501199A5 (enExample) | 2021-11-25 |
| JP7230041B2 JP7230041B2 (ja) | 2023-02-28 |
Family
ID=64277870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543248A Active JP7230041B2 (ja) | 2017-10-26 | 2018-10-26 | Ｂ－ｒａｆキナーゼ阻害物質の結晶塩 |
| JP2023021816A Pending JP2023062074A (ja) | 2017-10-26 | 2023-02-15 | Ｂ－ｒａｆキナーゼ阻害物質の結晶塩 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023021816A Pending JP2023062074A (ja) | 2017-10-26 | 2023-02-15 | Ｂ－ｒａｆキナーゼ阻害物質の結晶塩 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11306086B2 (enExample) |
| EP (2) | EP3700530B1 (enExample) |
| JP (2) | JP7230041B2 (enExample) |
| KR (1) | KR102820822B1 (enExample) |
| CN (2) | CN111818924B (enExample) |
| AU (2) | AU2018355528B2 (enExample) |
| BR (1) | BR112020008248A2 (enExample) |
| CA (1) | CA3080324A1 (enExample) |
| ES (1) | ES2947411T3 (enExample) |
| IL (1) | IL274027B2 (enExample) |
| MX (1) | MX2020004148A (enExample) |
| MY (1) | MY203853A (enExample) |
| PH (1) | PH12020550485A1 (enExample) |
| SG (1) | SG11202003635TA (enExample) |
| WO (1) | WO2019084459A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2947411T3 (es) | 2017-10-26 | 2023-08-08 | Xynomic Pharmaceuticals Inc | Sales cristalinas de un campo inhibidor de quinasa B-RAF |
| JP2022069426A (ja) * | 2020-10-23 | 2022-05-11 | マイラン ラボラトリーズ リミテッド | テネリグリプチン２．５臭化水素酸塩のアモルファスを調製する方法 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| MXPA06005578A (es) * | 2003-11-17 | 2006-08-11 | Pfizer Prod Inc | Compuestos de pirrolopirimidina utiles en el tratamiento del cancer. |
| GB0423554D0 (en) * | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
| MY153898A (en) | 2005-06-22 | 2015-04-15 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| WO2007123892A2 (en) * | 2006-04-17 | 2007-11-01 | Arqule Inc. | Raf inhibitors and their uses |
| EP1914234A1 (en) * | 2006-10-16 | 2008-04-23 | GPC Biotech Inc. | Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors |
| WO2010042337A1 (en) | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
| TWI423980B (zh) * | 2009-09-28 | 2014-01-21 | Hoffmann La Roche | 苯并氧氮呯ｐｉ３ｋ抑制劑化合物及使用方法 |
| US8889684B2 (en) * | 2011-02-02 | 2014-11-18 | Boehringer Ingelheim International Gmbh | Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors |
| WO2013010679A1 (en) | 2011-07-15 | 2013-01-24 | Novartis Ag | Salts of aza-bicyclic di-aryl ethers and methods to make them or their precursors |
| EP2945628B1 (en) * | 2013-01-15 | 2020-04-15 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2016167340A1 (ja) | 2015-04-16 | 2016-10-20 | 日東電工株式会社 | Ｂｒａｆ遺伝子変異を有する細胞に対する細胞死誘導剤、当該細胞の増殖抑制剤及び当該細胞の増殖異常に起因する疾患の治療用医薬組成物 |
| CN105801584B (zh) * | 2016-03-16 | 2019-03-05 | 中国药科大学 | 新型芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| ES2947411T3 (es) | 2017-10-26 | 2023-08-08 | Xynomic Pharmaceuticals Inc | Sales cristalinas de un campo inhibidor de quinasa B-RAF |
-
2018
- 2018-10-26 ES ES18801183T patent/ES2947411T3/es active Active
- 2018-10-26 MX MX2020004148A patent/MX2020004148A/es unknown
- 2018-10-26 MY MYPI2020001994A patent/MY203853A/en unknown
- 2018-10-26 US US16/759,187 patent/US11306086B2/en active Active
- 2018-10-26 CN CN201880081003.9A patent/CN111818924B/zh active Active
- 2018-10-26 AU AU2018355528A patent/AU2018355528B2/en active Active
- 2018-10-26 JP JP2020543248A patent/JP7230041B2/ja active Active
- 2018-10-26 EP EP18801183.7A patent/EP3700530B1/en active Active
- 2018-10-26 CA CA3080324A patent/CA3080324A1/en active Pending
- 2018-10-26 BR BR112020008248-1A patent/BR112020008248A2/pt not_active IP Right Cessation
- 2018-10-26 IL IL274027A patent/IL274027B2/en unknown
- 2018-10-26 SG SG11202003635TA patent/SG11202003635TA/en unknown
- 2018-10-26 KR KR1020207014962A patent/KR102820822B1/ko active Active
- 2018-10-26 EP EP23167989.5A patent/EP4245758A3/en not_active Withdrawn
- 2018-10-26 CN CN202310913355.9A patent/CN116942672B/zh active Active
- 2018-10-26 WO PCT/US2018/057792 patent/WO2019084459A1/en not_active Ceased
-
2020
- 2020-04-24 PH PH12020550485A patent/PH12020550485A1/en unknown
-
2022
- 2022-02-17 AU AU2022201044A patent/AU2022201044B2/en active Active
- 2022-03-11 US US17/692,695 patent/US11753409B2/en active Active
-
2023
- 2023-02-15 JP JP2023021816A patent/JP2023062074A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102961371B1 (ko) | Dna-의존적 단백질 키나제 억제제 | |
| KR102965826B1 (ko) | 헤테로고리 화합물, 이의 제조 방법 및 이의 용도 | |
| KR102589886B1 (ko) | 선택적 에스트로겐 수용체 분해제 | |
| KR102236605B1 (ko) | 피리도피리미딘온 cdk2/4/6 억제제 | |
| US20240124442A1 (en) | Tricyclic-amido-bicyclic prmt5 inhibitors | |
| US8653064B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido[5,4-D][2]benzazepin-2-yl]amino}-2-methoxybenzoate | |
| RU2578608C2 (ru) | Новое имидазооксазиновое соединение или его соль | |
| CN112839715A (zh) | 抑制shp2活性化合物的制造方法 | |
| US9890168B2 (en) | 2,4-disubstituted 7H-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof | |
| CN110546145B (zh) | 一种氮杂芳基衍生物、其制备方法和在药学上的应用 | |
| US11746109B2 (en) | Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate | |
| CN111643504A (zh) | Akt抑制剂化合物和化疗剂的组合以及使用方法 | |
| Schiemann et al. | The discovery and optimization of hexahydro-2H-pyrano [3, 2-c] quinolines (HHPQs) as potent and selective inhibitors of the mitotic kinesin-5 | |
| KR20190086442A (ko) | 피리딘 화합물 | |
| WO2017085053A1 (en) | Novel compounds as inhibitors of dna methyltransferases | |
| JP2018188465A (ja) | 結晶性ｆｇｆｒ４阻害剤化合物およびその使用 | |
| HUE029343T2 (en) | Quinolylpyrrolo-pyrimidyl fused ring compounds and salts thereof | |
| KR20180117697A (ko) | 피리디닐아미노피리미딘 유도체의 염, 그의 제조 방법, 및 그의 용도 | |
| Wang et al. | New palbociclib analogues modified at the terminal piperazine ring and their anticancer activities | |
| TWI780077B (zh) | 噻吩並嘧啶類化合物、其製備方法、藥用組合物及其應用 | |
| Song et al. | Facile synthesis and antitumor activity of novel 2-trifluoromethylthieno [2, 3-d] pyrimidine derivatives | |
| JP7493207B2 (ja) | がんの予防又は治療剤 | |
| US20240254130A1 (en) | Salt and solid forms of a kinase inhibitor | |
| CN103044460B (zh) | 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用 | |
| RU2020116763A (ru) | Кристаллические соли ингибитора b-raf-киназы |